News - Ansh Labs

Oxyntomodulin and Glicentin: Novel Biomarkers of Gastrointestinal and Metabolic Disorders

March 1, 2021

New Publication: The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital mortality

March 1, 2021

MenoCheck® – FDA cleared as an aid in the determination of menopausal status

November 2, 2018

Emerging Biomarkers for Reproductive Health offered by Ansh Labs

July 21, 2017

Endo 2017 Review: GDF-9, BMP-15, and more

April 18, 2017

Our Expertise

Our scientists and advisors are experts in immunoassay development. Our team began working together at Diagnostic Systems Laboratories (DSL) where we enjoyed 25 years of developing novel assays, exploring new biomarkers with key opinion leaders, developing intellectual property, and building relationships with our customers around the world. We excel at developing immunoassays from concept to fully validated assays. The efficiency of our monoclonal antibody development process enables us to produce and screen more antibodies to optimize pairs for a better immunoassay. Our core strength is research and development.

FIND OUT MORE